Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma

BACKGROUND: Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P = 0.130), and improved response ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Avinash, Towers, Christopher, Willenbrock, Frances, Brant, Roz, Hodgson, Darren Richard, Sharpe, Alan, Smith, Paul, Cutts, Anthony, Schuh, Anna, Asher, Ruth, Myers, Kevin, Love, Sharon, Collins, Linda, Wise, Adelyn, Middleton, Mark Roy, Macaulay, Valentine Moya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028919/
https://www.ncbi.nlm.nih.gov/pubmed/31839677
http://dx.doi.org/10.1038/s41416-019-0673-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028919/
https://www.ncbi.nlm.nih.gov/pubmed/31839677
http://dx.doi.org/10.1038/s41416-019-0673-5

Ejemplares similares